[en] Background and purpose: The identification of potent and selective radioligands for the mapping of 5-HT receptors is interesting both for clinical and experimental research. The aim of this study was to compare the potency of a new putative 5-HT1A receptor antagonist, p-DMPPF, (4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]-ethyl] piperazine) with that of the well-known 5-HT1A antagonists, WAY-100635(N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide) and its fluorobenzoyl analogue, p-MPPF (4-(2-methoxyphenyl)-1-[2'-[N-(2''-pyridinyl)p-fluorobenzamido] ethyl] piperazine). Experimental approach: Single cell extracellular recordings of dorsal raphe (DR) neurones were performed in rat brain slices. The potency of each compound at antagonizing the effect of the 5-HT1A agonist, 8-OH-DPAT [8-hydroxy-2-(di-npropylamino)tetraline], was quantified using the Schild equation. The pharmacological profile of p-DMPPF was defined using competition binding assays. Key results: Consistently with a 5-HT1A receptor antagonist profile, incubation of slices with an equimolar (10 nM) concentration of each compound markedly reduced the inhibitory effect of 8-OH-DPAT on the firing rate of DR neurones, causing a significant rightward shift in its concentration-response curve. The rank order of potency of the antagonists was WAY-100635 > p-DMPPF >= p-MPPF. The sensitivity of DR neurones to the inhibitory effect of 8-OH-DPAT was found to be heterogeneous. The binding experiments demonstrated that p-DMPPF is highly selective for 5-HT1A receptors, with a K-i value of 7 nM on these receptors. Conclusions and implications: The potency of the new compound, p-DMPPF, as a 5-HT1A antagonist is similar to that of p-MPPF in our electrophysiological assay. Its selectivity towards 5-HT1A receptors makes it a good candidate for clinical development.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Defraiteur, Caroline ; Université de Liège - ULiège > Centre de recherches du cyclotron
Plenevaux, Alain ; Université de Liège - ULiège > Centre de recherches du cyclotron
Scuvée-Moreau, Jacqueline ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie - Département des sciences biomédicales et précliniques
Rouchet, Nathalie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie
Goblet, David ; Université de Liège - ULiège > Centre de recherches du cyclotron
Luxen, André ; Université de Liège - ULiège > Département de chimie (sciences) > Chimie organique de synthèse - Centre de recherches du cyclotron
Seutin, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie
Language :
English
Title :
Characterization of 4-(2-hydroxyphenyl)-1-[2 '-[N-(2 ''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist
Aghajanian GK, Sprouse JS, Sheldon P, Rasmussen K (1990). Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Ann NY Acad Sci 600: 93-103.
Allers KA, Sharp T (2003). Neurochemical and anatomical identification of fast- and slow-firing neurons in the rat dorsal raphe nucleus using juxtacellular labeling methods in vivo. Neuroscience 122: 193-204.
Andree B, Halldin C, Pike VW, Gunn RN, Olsson H, Farde L (2002). The PET radioligand [carbonyl- 11C]desmethyl-WAY-100635 binds to 5-HT1A receptors and provides a higher radioactive signal than [carbonyl- 11C]WAY-100635 in the human brain. J Nucl Med 43: 292-303.
Beck SG, Pan Y-Z, Akanwa Adaure C, Kirby Lynn G (2004). Median and dorsal raphe neurons are not electrophysiologically identical. J Neurophysiol 91: 994-1005.
Bowery B, Rothwell LA, Seabrook GR (1994). Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol 112: 873-880.
Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E et al. (2000). PET evaluation of [ 18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl Med Biol 27: 493-497.
Day HEW, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF et al. (2004). Differential expression of 5HT-1A, a1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, g-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J Comp Neurol 474: 364-378.
Defraiteur C, Lemaire C, Luxen A, Plenevaux A (2006). Radiochemical synthesis and tissue distribution of p-[ 18F]DMPPF, a new 5-HT 1A ligand for PET, in rats. Nucl Med Biol 33: 667-675.
Fletcher A, Cliffe IA, Dourish CT (1993). Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci 14: 441-448.
Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE et al. (1996). Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73: 337-353.
Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y et al. (1995). A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol 281: 81-88.
Frazer A, Maayani S, Wolfe BB (1990). Subtypes of receptors for serotonin. Annu Rev Pharmacol Toxicol 30: 307-348.
Hamon M, Gozlan H, El Mestikawy S, Emerit MB, Bolanos F, Schechter L (1990). The central 5-HT1A receptors: pharmacological, biochemical, functional, and regulatory properties. Ann NY Acad Sci. 600: 114-131.
Hartig PR, Adham N, Zgombick J, Macchi M, Kao HT, Schechter L et al. (1993). Serotonin receptor subtypes. Psychopharmacology Ser 10 (Clin Pharmacol Psychiatry): 15-25.
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ et al. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157-203.
Kirby LG, Pernar L, Valentino RJ, Beck SG (2003). Distinguishing characteristics of serotonin and non-serotonin-containing cells in the dorsal raphe nucleus: electrophysiological and immunohistochemical studies. Neuroscience 116: 669-683.
Kung HF, Stevenson DA, Zhuang Z-P, Kung M-P, Frederick D, Hurt SD (1996). New 5-HT1A receptor antagonist: [ 3H]p-MPPF. Synapse 23: 344-346.
Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Birhaye C et al. (1998). High-yield radiosynthesis and preliminary in vivo evaluation of p-[ 18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 25: 343-350.
Lu J, Jhou TC, Saper CB (2006). Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 26: 193-202.
Marinelli S, Schnell SA, Hack SP, Christie MJ, Wessendorf MW, Vaughan CW (2004). Serotonergic and non-serotonergic dorsal raphe neurons are pharmacologically and electrophysiologically heterogeneous. J Neurophysiol 92: 3532-3537.
Pike VW, Halldin C, McCarron JA, Lundkvist C, Hirani E, Olsson H et al. (1998). [carbonyl- 11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 25: 338-346.
Plenevaux A, Lemaire C, Aerts J, Lacan G, Rubins D, Melega WP et al. (2000). [ 18F]p-MPPF: a radiolabeled antagonist for the study of 5-HT1A receptors with PET. Nucl Med Biol 27: 467-471.
Rogawski MA, Aghajanian GK (1981). Serotonin autoreceptors on dorsal raphe neurons: structure-activity relationships of tryptamine analogs. J Neurosci 1: 1148-1154.
Seutin V, Scuvee-Moreau J, Massotte L, Dresse A (1990). Effect of BHT920 on monoaminergic neurons of the rat brain. Naunyn Schmiedebergs Arch Pharmacol 342: 502-507.
Sprouse JS (1991). Inhibition of dorsal raphe cell firing by MDL 73005EF, a novel 5-HT1A receptor ligand. Eur J Pharmacol 201: 163-169.
Sprouse JS, Aghajanian GK (1987). Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1: 3-9.
Testa R, Guarneri L, Poggesi E, Angelico P, Velasco C, Ibba M et al. (1999). Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: comparison with WAY-100635. J Pharmacol Exp Ther 290: 1258-1269.
Vandermaelen CP, Aghajanian GK (1983). Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289: 109-119.
Williams JT, Colmers WF, Pan ZZ (1988). Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons in vitro. J Neurosci 8: 3499-3506.
Wilson AA, DaSilva JN, Houle S (1996). [ 18F]Fluoroalkyl analogs of the potent 5-HT1A antagonist WAY 100635: radiosyntheses and in vivo evaluation. Nucl Med Biol 23: 487-490.
Zhuang ZP, Kung MP, Kung HF (1993). Synthesis of (R,S)-trans-8-hydroxy-2- [N-n-propyl-N-(3′-iodo-2′-propenyl)amino]tetralin (trans 8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem 36: 3161-3165.
Zhuang Z-P, Kung M-P, Kung HF (1994). Synthesis and evaluation of 4-(2′-methoxyphenyl)-1-[2′-[N-(2″-pyridinyl) -p-iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J Med Chem 37: 1406-1407.
